Japan· JP-3961007F1018
グリクラジド
A gliclazide product containing グリクラジド, registered in Japan, on the national reimbursement list. The same ATC class is registered in 14 of our 19 countries.
Checked against MHLW / PMDA (Japan) on
Informational only — not a medical device.
Where it is registered
Gliclazide is registered in 14 of 19 countries.
Countries holding a registration under ATC A10BB09 (gliclazide), each read from that country’s own register.
- This record: Japan, from MHLW / PMDA (Japan)
- 7 of them publish a price we can compare per daily dose
Gliclazide · ATC A10BB09
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Franceprice
- Germany
- Icelandprice
- Ireland
- Italyprice
- Japan
- Netherlands
- Polandprice
- Switzerlandprice
- United Kingdom
Price per daily dose
What a daily dose of gliclazide costs, country by country.
Normalised to the WHO defined daily dose (60 mg), the median price runs from $0.11 in France to $0.61 in Switzerland — a ×5.5 gap.
- 3 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Gliclazide · price per daily dose (60 mg)
USD · FX 28 Sept 2026
- CH Switzerland$0.61
- IT Italy$0.26
- FR France$0.11
The record
At a glance
MHLW / PMDA (Japan)- Active substance
- グリクラジド
- Manufacturer
- —
- Country
- Japan (JP)
- ATC code
- A10BB09
- ATC class
- Gliclazide
- Defined daily dose
- 60 mg, O
- Reimbursed
- Yes
- Source register
- MHLW / PMDA (Japan)
- Last checked
- September 25, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
5 interactions on record for gliclazide.
Mechanism, severity and management for each pair, from a commercially licensed source — included with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Gliclazide · interactions on record
5 records
5 more interactions with mechanism and management, from a commercially licensed source.
Sign in to checkSame class
Other records under A10BB09
Gliclazide, as other registers publish it.
- CanadaAG-GLICLAZIDE MRANGITA PHARMA INC.
- CanadaAG-GLICLAZIDE MRANGITA PHARMA INC.
- CanadaAPO-GLICLAZIDEAPOTEX INC
- CanadaAPO-GLICLAZIDE MRAPOTEX INC
- CanadaAPO-GLICLAZIDE MRAPOTEX INC
- United KingdomBilxona 30mg modified-release tabletsAccord-UK Ltd
- United KingdomBilxona 60mg modified-release tabletsActavis UK Ltd
- United KingdomBilxona 60mg modified-release tabletsAccord-UK Ltd
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of MHLW / PMDA (Japan). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/fb4a3931-75d7-44f7-a6ba-64c5c7a93410 GET /v1/drugs/fb4a3931-75d7-44f7-a6ba-64c5c7a93410?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"spec": "４０ｍｇ１錠",
"marks": null,
"source": "mhlw",
"remarks": null,
"yj_code": "3961007F1018",
"category": "内用薬",
"price_yen": 6.3,
"generic_name": "グリクラジド",
"product_name_jp": null,
"therapeutic_class": "3961",
"transitional_expiry": "R9.3.31まで"
}See everything about gliclazide.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.